IRS-1 Polyclonal Antibody / Insulin Receptor Substrate 1 Polyclonal Antibody (R31636)

IRS-1 Polyclonal Antibody Detection in A549, MM453 and Jurkat Cells by WB. Western blot testing of human A549 (lane 1), MM453 (lane 2), and Jurkat (lane 3) cell lysates with IRS-1 Polyclonal Antibody shows strong, discrete high-molecular-weight bands in all three samples. The major signals migrate at approximately 150-160 kDa, within the reported 132-185 kDa range for IRS1 associated with differences in phosphorylation state. Relatively little additional reactivity is visible across the displayed molecular weight range. The consistent high-molecular-weight bands demonstrate detection of IRS1 in three human cell lines using this Insulin Receptor Substrate 1 Polyclonal Antibody.

IRS-1 Polyclonal Antibody Detection of Recombinant Human IRS1 Protein by WB. Western blot testing of 0.5 ng recombinant human IRS1 protein with IRS-1 Polyclonal Antibody shows a strong, discrete band migrating at approximately 35-40 kDa. Because the recombinant protein represents a partial IRS1 construct rather than full-length endogenous protein, its migration should not be compared with the approximately 132-185 kDa range observed for cellular IRS1. The isolated signal demonstrates recognition of recombinant IRS1 antigen using this Insulin Receptor Substrate 1 Polyclonal Antibody.

IRS-1 Polyclonal Antibody Staining in Human Lung Cancer by IHC. Immunohistochemistry staining of FFPE human lung cancer tissue with IRS-1 Polyclonal Antibody shows brown immunoreactivity within tumor cells, with predominantly cytoplasmic staining and heterogeneous signal intensity across the tissue. Numerous nuclei remain comparatively unstained. The cellular distribution is consistent with the role of IRS1 as an intracellular signaling adaptor and demonstrates detection of IRS1 in human lung cancer using this Insulin Receptor Substrate 1 Polyclonal Antibody.

IRS-1 Polyclonal Antibody Staining in Human Intestinal Cancer by IHC. Immunohistochemistry staining of FFPE human intestinal cancer tissue with IRS-1 Polyclonal Antibody shows prominent brown immunoreactivity in malignant glandular epithelial cells. Staining is predominantly cytoplasmic and is especially evident along the epithelial cells surrounding glandular lumens, while much of the intervening stromal tissue shows weaker labeling. The distinct epithelial staining demonstrates detection of IRS1 in human intestinal cancer using this Insulin Receptor Substrate 1 Polyclonal Antibody.

IRS-1 Polyclonal Antibody Staining in Mouse Intestine by IHC. Immunohistochemistry staining of FFPE mouse intestine with IRS-1 Polyclonal Antibody shows brown immunoreactivity within the intestinal mucosa, with staining concentrated in epithelial cells and comparatively weak labeling in much of the surrounding tissue. The visible signal demonstrates cross-species detection of IRS1 in mouse intestinal tissue using this Insulin Receptor Substrate 1 Polyclonal Antibody.

IRS-1 Polyclonal Antibody Staining in Rat Intestine by IHC. Immunohistochemistry staining of FFPE rat intestine with IRS-1 Polyclonal Antibody shows heterogeneous brown immunoreactivity within intestinal tissue, including cytoplasmic labeling in epithelial and other cells surrounding glandular structures. Numerous nuclei remain negative, while staining intensity varies among cells and tissue regions. The observed labeling demonstrates detection of IRS1 in rat intestine using this Insulin Receptor Substrate 1 Polyclonal Antibody.

IRS-1 Polyclonal Antibody Staining in Rat Skeletal Muscle by IHC. Immunohistochemistry staining of FFPE rat skeletal muscle with IRS-1 Polyclonal Antibody shows brown cytoplasmic immunoreactivity within skeletal muscle fibers, with variable staining intensity across the field. Additional strong staining is visible in a small vascular-associated structure, while nuclei remain predominantly unstained. The muscle-fiber labeling demonstrates detection of IRS1 in rat skeletal muscle using this Insulin Receptor Substrate 1 Polyclonal Antibody.